Peer-influenced content. Sources you trust. No registration required. This is HCN.

MashupMDPembrolizumab vs. Chemotherapy for Microsatellite Instability-High or Mismatch Repair-Deficient Metastatic CRC

In this updated analysis of the KEYNOTE-177 study, although pembrolizumab continued to show durable antitumor activity and fewer treatment-related adverse events compared with chemotherapy, there was no significant difference in overall survival between the two treatment groups.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form